Nuveen LLC Makes New $5.12 Million Investment in Integra LifeSciences Holdings Corporation $IART

Key Points

• Nuveen LLC invested approximately $5.12 million in Integra LifeSciences Holdings, acquiring 232,742 shares during the first quarter.
• Multiple hedge funds have recently altered their positions in Integra LifeSciences, with 84.78% of its shares owned by institutional investors.
• Analysts have lowered their price targets for Integra LifeSciences, with an average target of $18.63 and a consensus rating of "Reduce" based on varied outlooks from different brokerages.

Nuveen LLC purchased a new stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 232,742 shares of the life sciences company's stock, valued at approximately $5,118,000. Nuveen LLC owned about 0.30% of Integra LifeSciences at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of IART. Arizona State Retirement System boosted its stake in Integra LifeSciences by 4.2% during the first quarter. Arizona State Retirement System now owns 19,894 shares of the life sciences company's stock valued at $437,000 after buying an additional 795 shares during the period. Envestnet Asset Management Inc. boosted its holdings in Integra LifeSciences by 4.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 27,527 shares of the life sciences company's stock valued at $605,000 after acquiring an additional 1,204 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Integra LifeSciences by 3.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock valued at $872,000 after acquiring an additional 1,437 shares during the period. MetLife Investment Management LLC increased its holdings in Integra LifeSciences by 5.3% during the 4th quarter. MetLife Investment Management LLC now owns 41,749 shares of the life sciences company's stock valued at $947,000 after purchasing an additional 2,111 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Integra LifeSciences by 16.3% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,811 shares of the life sciences company's stock valued at $370,000 after purchasing an additional 2,357 shares during the period. 84.78% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. JMP Securities dropped their price target on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. JPMorgan Chase & Co. lowered their price objective on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Finally, Wells Fargo & Company lowered their price objective on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Reduce" and an average target price of $18.43.

Integra LifeSciences Stock Performance

NASDAQ IART traded up $0.29 on Friday, hitting $15.13. 1,189,457 shares of the company traded hands, compared to its average volume of 1,475,275. The company has a current ratio of 1.23, a quick ratio of 0.73 and a debt-to-equity ratio of 1.18. The business's 50 day moving average price is $13.05 and its 200-day moving average price is $16.08. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -2.32, a P/E/G ratio of 0.84 and a beta of 1.16. Integra LifeSciences Holdings Corporation has a 52-week low of $11.06 and a 52-week high of $27.13.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 earnings per share for the quarter, beating analysts' consensus estimates of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The firm had revenue of $415.61 million for the quarter, compared to analysts' expectations of $395.06 million. During the same period in the previous year, the firm earned $0.63 EPS. The business's quarterly revenue was down .6% on a year-over-year basis. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Equities analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.